Evidence map›Paper›PMID 39365963›Full record

ArticleJCO clinical cancer informatics2024

Development and Portability of a Text Mining Algorithm for Capturing Disease Progression in Electronic Health Records of Patients With Stage IV Non-Small Cell Lung Cancer.

M V Verschueren, H Abedian Kalkhoran, M Deenen, B E E M van den Borne, J Zwaveling, L E Visser, L T Bloem, B J M Peters, E M W van de Garde

Abstract read
In one paragraph

Article in JCO clinical cancer informatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M V VerschuerenDepartment of Clinical Pharmacy, St Antonius Hospital, Utrecht, the Netherlands.ORCID 0000-0002-2448-9168
H Abedian KalkhoranDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-6279-6310
M DeenenDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-4389-6420
B E E M van den BorneDepartment of Respiratory Medicine, Catharina Hospital, Eindhoven, the Netherlands.
J ZwavelingDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-6080-6183
L E VisserDepartment of Pharmacy, Haga Teaching Hospital, The Hague, the Netherlands.
L T BloemDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-0014-8625
B J M PetersDepartment of Clinical Pharmacy, St Antonius Hospital, Utrecht, the Netherlands.ORCID 0009-0004-1321-3969
E M W van de GardeDepartment of Clinical Pharmacy, St Antonius Hospital, Utrecht, the Netherlands.ORCID 0000-0002-1334-2144

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective was to develop and evaluate the portability of a text mining algorithm for prospectively capturing disease progression in electronic health record (EHR) data of patients with metastatic non-small cell lung cancer (mNSCLC) treated with immunochemotherapy.

methodsThis study used EHR data from patients with mNSCLC receiving immunochemotherapy (between October 1, 2018, and December 31, 2022) in four Dutch hospitals. A text mining algorithm for capturing disease progression was developed in hospitals 1 and 2 and then transferred to hospitals 3 and 4 to evaluate portability. Performance metrics were calculated by comparing its outcomes with manual chart review. In addition, data were simulated to come available over time to assess performance in real-time applications. Median progression-free survival (PFS) was calculated using the Kaplan-Meier method to compare text mining with manual chart review.

resultsDuring development and portability, the text mining algorithm performed well in capturing disease progression, with all performance scores >90%. When real-time performance was simulated, the performance scores in all four hospitals exceeded 90% from week 15 after the start of follow-up. Although the exact progression dates varied in 46 patients of 157 patients with progressive disease, the number of patients labeled with progression too early (n = 24) and too late (n = 22) was well balanced with discrepancies ranging from -116 to 384 days. Nevertheless, the PFS curves constructed with text mining and manual chart review were highly similar for each hospital.

conclusionIn this study, an accurate text mining algorithm for capturing disease progression in the EHR data of patients with mNSCLC was developed. The algorithm was portable across different hospitals, and the performance over time was good, making this an interesting approach for prospective follow-up of multicenter cohorts.

Indexed as

AlgorithmsCarcinoma, Non-Small-Cell LungData MiningDisease ProgressionElectronic Health RecordsLung NeoplasmsNeoplasm StagingAgedFemaleHumansMaleMiddle Aged

Identifiers

PMID39365963
PMCPMC11469628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.